Pharmacologic modulation of ACE2 expression

Angiotensin-converting enzyme 2 (ACE2) is an enzymatically active homologue of angiotensin-converting enzyme that degrades angiotensin I, angiotensin II, and other peptides. Recent studies have shown that under pathologic conditions, ACE2 expression in the kidney is altered. In this review, we brief...

Descripción completa

Detalles Bibliográficos
Autores principales: Soler, María José, Barrios, Clara, Oliva, Raymond, Batlle, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Current Science Inc. 2008
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089438/
https://www.ncbi.nlm.nih.gov/pubmed/18775121
http://dx.doi.org/10.1007/s11906-008-0076-0
_version_ 1783509736474279936
author Soler, María José
Barrios, Clara
Oliva, Raymond
Batlle, Daniel
author_facet Soler, María José
Barrios, Clara
Oliva, Raymond
Batlle, Daniel
author_sort Soler, María José
collection PubMed
description Angiotensin-converting enzyme 2 (ACE2) is an enzymatically active homologue of angiotensin-converting enzyme that degrades angiotensin I, angiotensin II, and other peptides. Recent studies have shown that under pathologic conditions, ACE2 expression in the kidney is altered. In this review, we briefly summarize recent studies dealing with pharmacologic interventions that modulate ACE2 expression. ACE2 amplification may have a potential therapeutic role for kidney disease and hypertension.
format Online
Article
Text
id pubmed-7089438
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Current Science Inc.
record_format MEDLINE/PubMed
spelling pubmed-70894382020-03-23 Pharmacologic modulation of ACE2 expression Soler, María José Barrios, Clara Oliva, Raymond Batlle, Daniel Curr Hypertens Rep Article Angiotensin-converting enzyme 2 (ACE2) is an enzymatically active homologue of angiotensin-converting enzyme that degrades angiotensin I, angiotensin II, and other peptides. Recent studies have shown that under pathologic conditions, ACE2 expression in the kidney is altered. In this review, we briefly summarize recent studies dealing with pharmacologic interventions that modulate ACE2 expression. ACE2 amplification may have a potential therapeutic role for kidney disease and hypertension. Current Science Inc. 2008-10-16 2008 /pmc/articles/PMC7089438/ /pubmed/18775121 http://dx.doi.org/10.1007/s11906-008-0076-0 Text en © Current Medicine Group LLC 2008 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Soler, María José
Barrios, Clara
Oliva, Raymond
Batlle, Daniel
Pharmacologic modulation of ACE2 expression
title Pharmacologic modulation of ACE2 expression
title_full Pharmacologic modulation of ACE2 expression
title_fullStr Pharmacologic modulation of ACE2 expression
title_full_unstemmed Pharmacologic modulation of ACE2 expression
title_short Pharmacologic modulation of ACE2 expression
title_sort pharmacologic modulation of ace2 expression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089438/
https://www.ncbi.nlm.nih.gov/pubmed/18775121
http://dx.doi.org/10.1007/s11906-008-0076-0
work_keys_str_mv AT solermariajose pharmacologicmodulationoface2expression
AT barriosclara pharmacologicmodulationoface2expression
AT olivaraymond pharmacologicmodulationoface2expression
AT batlledaniel pharmacologicmodulationoface2expression

Ejemplares similares